Praxis Precision Medicines vs Xenon Pharmaceuticals
PRAX and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRAX and XENE compare
Praxis Precision Medicines is the larger company, worth 2.3 times as much as Xenon Pharmaceuticals ($9.2B against $3.9B).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRAX | XENE |
|---|---|---|
| Size and price | ||
| Market cap | $9.2B | $3.9B |
| Share price | $328.13 | $40.48 |
| Change, 1 year | 78.7% | 2.0% |
| Change, 5 years | 17.2% | 39.6% |
| Beta (5Y) | 1.65 | 0.62 |
| Employees | 168 | 370 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 7.3× | 3.4× (better) |
| FCF yield | −3.5% (better) | −9.1% |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | – | −25.3% |
| Profitability | ||
| Return on equity | −44.8% (better) | −50.3% |
| Return on invested capital | – | −251% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 14.53 | 21.19 (better) |
| Altman Z-score | 102.83 (better) | 41.77 |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 121% | 104% |
| Held by insiders | 0.72% | 0.17% |
| Insider net buying, 12 months | −$3.6M (better) | −$20.3M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 15.2% | 7.6% |
Go deeper
- PRAX stock overview
- PRAX income statement
- PRAX valuation and score
- XENE stock overview
- XENE income statement
- XENE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.